Nachrichten zur Royalty Pharma plc Aktie

BRAIN Biotech AG schließt eine Vereinbarung über die Monetarisierung von Lizenzgebühren in Höhe von bis zu 128,88 Mio. EUR für…

Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general…

Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the YORVIPATH® U.S. commercial launch, and general…

…

…

NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX)…

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has…

It is hard to get excited after looking at Royalty Pharmas (NASDAQ:RPRX) recent performance, when its stock has...…

Agios Pharmaceuticals (AGIO) agrees to sell to Royalty Pharma the rights to royalties on potential net sales of a brain…

Earnings call: Royalty Pharma reports robust growth and strategic acquisitions…

…

NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it will…

NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX)…